Pituitary gland volume in patients with schizophrenia, subjects at ultra high-risk of developing psychosis and healthy controls: A systematic review and meta-analysis

Psychoneuroendocrinology

Volumn 38, Issue 11, 2013, Pages 2394-2404

  Nordholm, Dorte ^a,b   Krogh, Jesper ^a   Mondelli, Valeria ^c   Dazzan, Paola ^c   Pariante, Carmine ^c   Nordentoft, Merete ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b Mental Health Center Glostrup   (Denmark)

^c KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

HPA axis; Hypofysis; Meta analysis; MRI; Pituitary; Psychosis; Schizophrenia

Indexed keywords

NEUROLEPTIC AGENT;

ADULT; AGE DISTRIBUTION; BRAIN RADIOGRAPHY; BRAIN SIZE; CLINICAL EVALUATION; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE DURATION; DRUG EFFECT; FEMALE; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; ORGAN SIZE; PITUITARY GLAND VOLUME; PRIORITY JOURNAL; REVIEW; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SEX DIFFERENCE; SUBSTANCE ABUSE; SYSTEMATIC REVIEW;

HPA AXIS; HYPOFYSIS; META-ANALYSIS; MRI; PITUITARY; PSYCHOSIS; SCHIZOPHRENIA;

ANTIPSYCHOTIC AGENTS; CASE-CONTROL STUDIES; HUMANS; HYPERTROPHY; PITUITARY GLAND; PSYCHOTIC DISORDERS; SCHIZOPHRENIA; SCHIZOTYPAL PERSONALITY DISORDER; SEX CHARACTERISTICS;

EID: 84886085446     PISSN: 03064530     EISSN: 18733360     Source Type: Journal    
DOI: 10.1016/j.psyneuen.2013.06.030     Document Type: Review

References (51)

1. Aas M., Dazzan P., Mondelli V., Toulopoulou T., Reichenberg A., Di Forti M., Fisher H.L., Handley R., Hepgul N., Marques T., Miorelli A., Taylor H., Russo M., Wiffen B., Papadopoulos A., Aitchison K.J., Morgan C., Murray R.M., Pariante C.M. Abnormal cortisol awakening response predicts worse cognitive function in patients with first-episode psychosis. Psychol. Med. 2011, 41:463-476.
2. Aiello G., Horowitz M., Hepgul N., Pariante C.M., Mondelli V. Stress abnormalities in individuals at risk for psychosis: a review of studies in subjects with familial risk or with "at risk" mental state. Psychoneuroendocrinology 2012, 37:1600-1613.
3. Andreasen N.C., Flaum M., Arndt S. The Comprehensive Assessment of Symptoms and History (CASH). An instrument for assessing diagnosis and psychopathology. Arch. Gen. Psychiatry 1992, 49:615-623.
4. Axelson D.A., Doraiswamy P.M., Boyko O.B., Rodrigo E.P., McDonald W.M., Ritchie J.C., Patterson L.J., Ellinwood E.H., Nemeroff C.B., Krishnan K.R. In vivo assessment of pituitary volume with magnetic resonance imaging and systematic stereology: relationship to dexamethasone suppression test results in patients. Psychiatry Res. 1992, 44:63-70.
5. Belvederi M.M., Pariante C.M., Dazzan P., Hepgul N., Papadopoulos A.S., Zunszain P., Di Forti M., Murray R.M., Mondelli V. Hypothalamic-pituitary-adrenal axis and clinical symptoms in first-episode psychosis. Psychoneuroendocrinology 2012, 37:629-644.
6. Borestein M., Hedges L.H.J., Rothstein H. Comprehensive Meta Analysis Version 2 2005, Biostat, Englewood, NJ.
7. Buschlen J., Berger G.E., Borgwardt S.J., Aston J., Gschwandtner U., Pflueger M.O., Kuster P., Radu E.W., Stieglitz R.D., Riecher-Rossler A. Pituitary volume increase during emerging psychosis. Early Intervention in Psychiatry 2010, Conference, November.
8. Buschlen J., Berger G.E., Borgwardt S.J., Aston J., Gschwandtner U., Pflueger M.O., Kuster P., Radu E.W., Stieglitz R.D., Riecher-Rossler A. Pituitary volume increase during emerging psychosis. Schizophr. Res. 2011, 125:41-48.
9. Danese A., Pariante C.M., Brudaglio F., Dazzan P., Morgan K.D., Orr K.D., Fearon P., Hutchinson G., Velakoulis D., Soulsby B., Mallett R., Leff J., Murray R.M. Increased pituitary volume in patients of the AESOP First-Onset Psychosis study. Int. J. Neuropsychopharmacol. 2004, 7:S392-S393.
10. Day F., Valmaggia L., Pariante C., Papadopoulos A., Papadopoulos I., McGuire P. Stress in people at high risk for psychosis. Eur. Psychiatry 2011, 26.
11. DerSimonian R., Laird N. Meta-analysis in clinical trials. Control. Clin. Trials 1986, 7:177-188.
12. Elster A.D. Modern imaging of the pituitary. Radiology 1993, 187:1-14.
13. Garner B.A., Pariante C.M., Wood S.J., Velakoulis D., Phillips L., Soulsby B., Brewer W., Smith D.J., Dazzan P., Yung A.R., Buuse M.V.D., McGorry P.D., Pantelis C. An MRI study of pituitary volume in individuals at ultra-high risk of developing psychosis. Int. J. Neuropsychopharmacol. 2004, 7:S223.
14. Garner B., Pariante C.M., Wood S.J., Velakoulis D., Phillips L., Soulsby B., Brewer W.J., Smith D.J., Dazzan P., Berger G.E., Yung A.R., van den Buuse M., Murray R., McGorry P.D., Pantelis C. Pituitary volume predicts future transition to psychosis in individuals at ultra-high risk of developing psychosis. Biol. Psychiatry 2005, 58:417-423.
15. Gertz B.J., Gardner D.G., Baxter J.D. Glucocorticoid control of rat growth hormone gene expression: effect on cytoplasmic messenger ribonucleic acid production and degradation. Mol. Endocrinol. 1987, 1:933-941.
16. Grams A.E., Gempt J., Stahl A., Forschler A. Female pituitary size in relation to age and hormonal factors. Neuroendocrinology 2010, 92:128-132.
17. Higgins J.P., Thompson S.G., Deeks J.J., Altman D.G. Measuring inconsistency in meta-analyses. BMJ 2003, 327:557-560.
18. Klomp A., Cedric P., Koolschijn M.P., Pol H.E.H., Kahn R.S., Van Haren N.E.M. Hypothalamus and pituitary volume in schizophrenia: a structural MRI study. Int. J. Neuropsychopharmacol. 2012, 15:281-288.
19. Large M., Nielssen O., Slade T., Harris A. Measurement and reporting of the duration of untreated psychosis. Early Interv. Psychiatry 2008, 2:201-211.
20. MacMaster F.P., El-Sheikh R., Upadhyaya A.R., Nutche J., Rosenberg D.R., Keshavan M. Effect of antipsychotics on pituitary gland volume in treatment-naive first-episode schizophrenia: a pilot study. Schizophr. Res. 2007, 92:207-210.
21. MacMaster F.P., Keshavan M., Mirza Y., Carrey N., Upadhyaya A.R., El-Sheikh R., Buhagiar C.J., Taormina S.P., Boyd C., Lynch M., Rose M., Ivey J., Moore G.J., Rosenberg D.R. Development and sexual dimorphism of the pituitary gland. Life Sci. 2007, 80:940-944.
22. McGorry P.D., Yung A.R., Phillips L.J., Yuen H.P., Francey S., Cosgrave E.M., Germano D., Bravin J., McDonald T., Blair A., Adlard S., Jackson H. Randomized controlled trial of interventions designed to reduce the risk of progression to first-episode psychosis in a clinical sample with subthreshold symptoms. Arch. Gen. Psychiatry 2002, 59:921-928.
23. Miller T.J., McGlashan T.H., Rosen J.L., Cadenhead K., Cannon T., Ventura J., McFarlane W., Perkins D.O., Pearlson G.D., Woods S.W. Prodromal assessment with the structured interview for prodromal syndromes and the scale of prodromal symptoms: predictive validity, interrater reliability, and training to reliability. Schizophr. Bull. 2003, 29:703-715.
24. Mondelli V., Cattaneo A., Belvederi M.M., Di Forti M., Handley R., Hepgul N., Miorelli A., Navari S., Papadopoulos A.S., Aitchison K.J., Morgan C., Murray R.M., Dazzan P., Pariante C.M. Stress and inflammation reduce brain-derived neurotrophic factor expression in first-episode psychosis: a pathway to smaller hippocampal volume. J. Clin. Psychiatry 2011, 72:1677-1684.
25. Mondelli V., Dazzan P., Gabilondo A., Tournikioti K., Walshe M., Marshall N., Schulze K.K., Murray R.M., McDonald C., Pariante C.M. Pituitary volume in unaffected relatives of patients with schizophrenia and bipolar disorder. Psychoneuroendocrinology 2008, 33:1004-1012.
26. Mondelli V., Dazzan P., Hepgul N., Di Forti M., Aas M., D'Albenzio A., Di Nicola M., Fisher H., Handley R., Marques T.R., Morgan C., Navari S., Taylor H., Papadopoulos A., Aitchison K.J., Murray R.M., Pariante C.M. Abnormal cortisol levels during the day and cortisol awakening response in first-episode psychosis: the role of stress and of antipsychotic treatment. Schizophr. Res. 2010, 116:234-242.
27. Mondelli V., Pariante C.M., Navari S., Aas M., D'Albenzio A., Di Forti M., Handley R., Hepgul N., Marques T.R., Taylor H., Papadopoulos A.S., Aitchison K.J., Murray R.M., Dazzan P. Higher cortisol levels are associated with smaller left hippocampal volume in first-episode psychosis. Schizophr. Res. 2010, 119:75-78.
28. Mondelli V., McDonald C., Gabilondo A., Tournikioti K., Walshe M., Marshall N., Schulze K., Murray R.M., Dazzan P., Pariante C.M. Increased pituitary volume is a familial risk factor for schizophrenia but not for bipolar disorder. Eur. Neuropsychopharmacol. 2007, 17:S404-S405.
29. Montejo A.L. Prolactin awareness: an essential consideration for physical health in schizophrenia. Eur. Neuropsychopharmacol. 2008, 18(Suppl. 2):S108-S114.
30. Nenadic I., Gaser C., Sauer H. Heterogeneity of brain structural variation and the structural imaging endophenotypes in schizophrenia. Neuropsychobiology 2012, 66:44-49.
31. Nicolo J.-P., Berger G.E., Garner B.A., Velakoulis D., Markulev C., Kerr M., McGorry P.D., Proffitt T.-M., McConchie M., Pantelis C., Wood S.J. The effect of atypical antipsychotics on pituitary gland volume in patients with first-episode psychosis. A longitudinal MRI study. Schizophr. Res. 2010, 116:49-54.
32. Norman R.M., Malla A.K. Duration of untreated psychosis: a critical examination of the concept and its importance. Psychol. Med. 2001, 31:381-400.
33. Pariante C.M. Pituitary volume in psychosis: the first review of the evidence. J. Psychopharmacol. 2008, 22:76-81.
34. Pariante C.M., Brudaglio F., Danese A., Dazzan P., Morgan K., Velakoulis D., Soulsby B., Mallett R., Leff J., Murray R. Increased pituitary volume in patients of the AESOP First-Onset Psychosis Study. Schizophr. Res. 2004, 67:99-100.
35. Pariante C.M., Dazzan P., Danese A., Morgan K.D., Brudaglio F., Morgan C., Fearon P., Orr K., Hutchinson G., Pantelis C., Velakoulis D., Jones P.B., Leff J., Murray R.M. Increased pituitary volume in antipsychotic-free and antipsychotic-treated patients of the AEsop first-onset psychosis study. Neuropsychopharmacology 2005, 30:1923-1931.
36. Pariante C.M., Vassilopoulou K., Velakoulis D., Phillips L., Soulsby B., Wood S.J., Brewer W., Smith D.J., Dazzan P., Yung A.R., Zervas I.M., Christodoulou G.N., Murray R., McGorry P.D., Pantelis C. Pituitary volume in psychosis. Br. J. Psychiatry 2004, 185:5-10.
37. Riecher-Rossler A., Aston J., Ventura J., Merlo M., Borgwardt S., Gschwandtner U., Stieglitz R.D. The Basel Screening Instrument for Psychosis (BSIP): development, structure, reliability and validity. Fortschr. Neurol. Psychiatr. 2008, 76:207-216.
38. Riecher-Rossler A., Kulkarni J. Estrogens and gonadal function in schizophrenia and related psychoses. Curr. Top. Behav. Neurosci. 2011, 8:155-171.
39. Riecher-Rossler A., Rossler W. The course of schizophrenic psychoses: what do we really know? A selective review from an epidemiological perspective. Eur. Arch. Psychiatry Clin. Neurosci. 1998, 248:189-202.
40. Shepherd A.M., Laurens K.R., Matheson S.L., Carr V.J., Green M.J. Systematic meta-review and quality assessment of the structural brain alterations in schizophrenia. Neurosci. Biobehav. Rev. 2012, 36:1342-1356.
41. Takahashi T., Suzuki M., Velakoulis D., Lorenzetti V., Soulsby B., Zhou S., Nakamura K., Seto H., Kurachi M., Pantelis C. Increased pituitary volume in schizophrenia spectrum disorders. Schizophr. Res. 2009, 108:114-121.
42. Takahashi T., Zhou S.Y., Nakamura K., Tanino R., Furuichi A., Kido M., Kawasaki Y., Noguchi K., Seto H., Kurachi M., Suzuki M. Longitudinal volume changes of the pituitary gland in patients with schizotypal disorder and first-episode schizophrenia. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 2011, 35:177-183.
43. Tournikioti K., Tansella M., Perlini C., Rambaldelli G., Cerini R., Versace A., Andreone N., Dusi N., Balestrieri M., Malago R., Gasparini A., Brambilla P. Normal pituitary volumes in chronic schizophrenia. Psychiatry Res. Neuroimag. 2007, 154:41-48.
44. Upadhyaya A.R., El-Sheikh R., Keshavan M.S. Pituitary volume in first episode psychosis: a structural MRI study. Biol. Psychiatry 2005, 57:114S.
45. Upadhyaya A.R., El-Sheikh R., MacMaster F.P., Diwadkar V.A., Keshavan M.S. Pituitary volume in neuroleptic-naive schizophrenia: a structural MRI study. Schizophr. Res. 2007, 90:266-273.
46. Walker E., Mittal V., Tessner K. Stress and the hypothalamic pituitary adrenal axis in the developmental course of schizophrenia. Annu. Rev. Clin. Psychol. 2008, 4:189-216.
47. Westlund K.N., Aguilera G., Childs G.V. Quantification of morphological changes in pituitary corticotropes produced by in vivo corticotropin-releasing factor stimulation and adrenalectomy. Endocrinology 1985, 116:439-445.
48. Yung A.R., Phillips L.J., McGorry P.D., McFarlane C.A., Francey S., Harrigan S., Patton G.C., Jackson H.J. Prediction of psychosis. A step towards indicated prevention of schizophrenia. Br. J. Psychiatry Suppl. 1998, 172:14-20.
49. Yung A.R., Phillips L.J., Yuen H.P., Francey S.M., McFarlane C.A., Hallgren M., McGorry P.D. Psychosis prediction: 12-month follow up of a high-risk ("prodromal") group. Schizophr. Res. 2003, 60:21-32.
50. Yung A.R., Yuen H.P., McGorry P.D., Phillips L.J., Kelly D., Dell'Olio M., Francey S.M., Cosgrave E.M., Killackey E., Stanford C., Godfrey K., Buckby J. Mapping the onset of psychosis: the Comprehensive Assessment of At-Risk Mental States. Aust. N. Z. J. Psychiatry 2005, 39:964-971.
51. Zubin J., Spring B. Vulnerability-a new view of schizophrenia. J. Abnorm. Psychol. 1977, 86:103-126.